Nibbelink D W, Torner J C, Henderson W G
Stroke. 1975 Nov-Dec;6(6):622-9. doi: 10.1161/01.str.6.6.622.
In this cooperative study among 13 institutions, 502 patients were treated with antifibrinolytic medication (epsilon-aminocaproic acid or tranexamic acid) within a 14-day period following rupture of an intracranial aneurysm. Mortality at the end of 14 days was 11.6%; proved rebleed rate was 12.7%. Patients with an internal carotid or anterior cerebral aneurysm had the highest mortality and rebleed rate. Most rebleeds occurred between the sixth and eleventh days following the initial bleed. Significantly higher mortality was reported among patients with cerebral vasospasm, yet rebleed rate was no different among those patients with or without vasospasm. The same pattern was observed among patients with a mean blood pressure value above and below 110 mm Hg. We conclude that antifibrinolytic therapy provides beneficial treatment to patients with recent onset subarachnoid hemorrhage (SAH) following rupture of an intracranial aneurysm.
在这项由13家机构参与的合作研究中，502例患者在颅内动脉瘤破裂后的14天内接受了抗纤维蛋白溶解药物治疗（ε-氨基己酸或氨甲环酸）。14天结束时的死亡率为11.6%；证实的再出血率为12.7%。颈内动脉或大脑前动脉瘤患者的死亡率和再出血率最高。大多数再出血发生在首次出血后的第六天至第十一天之间。据报道，脑血管痉挛患者的死亡率显著更高，但有或没有血管痉挛的患者的再出血率并无差异。平均血压值高于和低于110 mmHg的患者也观察到相同的模式。我们得出结论，抗纤维蛋白溶解疗法为近期发生颅内动脉瘤破裂后蛛网膜下腔出血（SAH）的患者提供了有益的治疗。
